Literature DB >> 18268071

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Stephane De Wit1, Caroline A Sabin, Rainer Weber, Signe Westring Worm, Peter Reiss, Charles Cazanave, Wafaa El-Sadr, Antonella d'Arminio Monforte, Eric Fontas, Matthew G Law, Nina Friis-Møller, Andrew Phillips.   

Abstract

OBJECTIVE: The aims of this study were to determine the incidence of diabetes among HIV-infected patients in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort, to identify demographic, HIV-related, and combination antiretroviral therapy (cART)-related factors associated with the onset of diabetes, and to identify possible mechanisms for any relationships found. RESEARCH DESIGN AND METHODS: D:A:D is a prospective observational study of 33,389 HIV-infected patients; diabetes is a study end point. Poisson regression models were used to assess the relation between diabetes and exposure to cART after adjusting for known risk factors for diabetes, CD4 count, lipids, and lipodystrophy.
RESULTS: Over 130,151 person-years of follow-up (PYFU), diabetes was diagnosed in 744 patients (incidence rate of 5.72 per 1,000 PYFU [95% CI 5.31-6.13]). The incidence of diabetes increased with cumulative exposure to cART, an association that remained significant after adjustment for potential risk factors for diabetes. The strongest relationship with diabetes was exposure to stavudine; exposures to zidovudine and didanosine were also associated with an increased risk of diabetes. Time-updated measurements of total cholesterol, HDL cholesterol, and triglycerides were all associated with diabetes. Adjusting for each of these variables separately reduced the relationship between cART and diabetes slightly. Although lipodystrophy was significantly associated with diabetes, adjustment for this did not modify the relationship between cART and diabetes.
CONCLUSION: Stavudine and zidovudine are significantly associated with diabetes after adjustment for risk factors for diabetes and lipids. Adjustment for lipodystrophy did not modify the relationship, suggesting that the two thymidine analogs probably directly contribute to insulin resistance, potentially through mitochondrial toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18268071      PMCID: PMC2746200          DOI: 10.2337/dc07-2013

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   17.152


  21 in total

1.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

Authors:  K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

2.  Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.

Authors:  Seng Khee Gan; Katherine Samaras; Campbell H Thompson; Edward W Kraegen; Andrew Carr; David A Cooper; Donald J Chisholm
Journal:  Diabetes       Date:  2002-11       Impact factor: 9.461

3.  Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy.

Authors:  D C Mynarcik; M A McNurlan; R T Steigbigel; J Fuhrer; M C Gelato
Journal:  J Acquir Immune Defic Syndr       Date:  2000-12-01       Impact factor: 3.731

4.  Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.

Authors:  Judith C Shlay; Fehmida Visnegarwala; Glenn Bartsch; Jack Wang; Grace Peng; Wafaa M El-Sadr; Cynthia Gibert; Donald Kotler; Carl Grunfeld; Subhasree Raghavan
Journal:  J Acquir Immune Defic Syndr       Date:  2005-02-01       Impact factor: 3.731

5.  Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.

Authors:  Todd T Brown; Stephen R Cole; Xiuhong Li; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs
Journal:  Arch Intern Med       Date:  2005-05-23

6.  Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution.

Authors:  Gary Meininger; Colleen Hadigan; Michael Laposata; Joanne Brown; Jessica Rabe; Joseph Louca; Negar Aliabadi; Steven Grinspoon
Journal:  Metabolism       Date:  2002-02       Impact factor: 8.694

7.  Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.

Authors:  Bruno Ledergerber; Hansjakob Furrer; Martin Rickenbach; Roger Lehmann; Luigia Elzi; Bernard Hirschel; Matthias Cavassini; Enos Bernasconi; Patrick Schmid; Matthias Egger; Rainer Weber
Journal:  Clin Infect Dis       Date:  2007-05-21       Impact factor: 9.079

8.  Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study.

Authors:  Phyllis C Tien; Michael F Schneider; Stephen R Cole; Alexandra M Levine; Mardge Cohen; Jack DeHovitz; Mary Young; Jessica E Justman
Journal:  AIDS       Date:  2007-08-20       Impact factor: 4.177

9.  PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.

Authors:  Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

10.  Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1.

Authors:  Mary Elizabeth Patti; Atul J Butte; Sarah Crunkhorn; Kenneth Cusi; Rachele Berria; Sangeeta Kashyap; Yoshinori Miyazaki; Isaac Kohane; Maura Costello; Robert Saccone; Edwin J Landaker; Allison B Goldfine; Edward Mun; Ralph DeFronzo; Jean Finlayson; C Ronald Kahn; Lawrence J Mandarino
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-27       Impact factor: 12.779

View more
  198 in total

1.  Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy.

Authors:  Claude Béténé A Dooko; Stephane De Wit; Jacqueline Neuhaus; Adrian Palfreeman; Rosalie Pepe; James S Pankow; James D Neaton
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

2.  Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy.

Authors:  Laura Galli; Stefania Salpietro; Gabriele Pellicciotta; Alberto Galliani; Piermarco Piatti; Hamid Hasson; Monica Guffanti; Nicola Gianotti; Alba Bigoloni; Adriano Lazzarin; Antonella Castagna
Journal:  Eur J Epidemiol       Date:  2012-06-22       Impact factor: 8.082

3.  Characteristics of Native Americans with HIV and implications for care.

Authors:  Christina Connel; Jeffrey S Stroup; Johnny R Stephens; Erica Martin
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-04

Review 4.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

5.  Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study.

Authors:  Raj K Medapalli; Chirag R Parikh; Kirsha Gordon; Sheldon T Brown; Adeel A Butt; Cynthia L Gibert; David Rimland; Maria C Rodriguez-Barradas; Chung-Chou H Chang; Amy C Justice; John Cijiang He; Christina M Wyatt
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

6.  Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men.

Authors:  Anne K Monroe; Wei Fu; Michelle N Zikusoka; Lisa P Jacobson; Mallory D Witt; Frank J Palella; Lawrence A Kingsley; Wendy S Post; Todd T Brown
Journal:  AIDS Res Hum Retroviruses       Date:  2015-03-09       Impact factor: 2.205

7.  New-onset type 2 diabetes mellitus among patients receiving HIV care at Newlands Clinic, Harare, Zimbabwe: retrospective cohort analysis.

Authors:  Cleophas Chimbetete; Catrina Mugglin; Tinei Shamu; Bindu Kalesan; Barbara Bertisch; Matthias Egger; Olivia Keiser
Journal:  Trop Med Int Health       Date:  2017-06-08       Impact factor: 2.622

8.  Inaccuracy of haemoglobin A1c among HIV-infected men: effects of CD4 cell count, antiretroviral therapies and haematological parameters.

Authors:  Laurence Slama; Frank J Palella; Alison G Abraham; Xiuhong Li; Corinne Vigouroux; Gilles Pialoux; Lawrence Kingsley; Jordan E Lake; Todd T Brown
Journal:  J Antimicrob Chemother       Date:  2014-08-04       Impact factor: 5.790

Review 9.  Alcohol Use and Human Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future Directions.

Authors:  Emily C Williams; Judith A Hahn; Richard Saitz; Kendall Bryant; Marlene C Lira; Jeffrey H Samet
Journal:  Alcohol Clin Exp Res       Date:  2016-09-22       Impact factor: 3.455

10.  Antiretroviral therapy modifies the genetic effect of known type 2 diabetes-associated risk variants in HIV-infected women.

Authors:  Melissa A Frasco; Roksana Karim; David Van Den Berg; Richard M Watanabe; Kathryn Anastos; Mardge Cohen; Stephen J Gange; Deborah R Gustafson; Chenglong Liu; Phyllis C Tien; Wendy J Mack; Celeste L Pearce
Journal:  AIDS       Date:  2014-07-31       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.